Global Blood Therapeutics

Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver treatments that provide hope to underserved patient communities. The company's primary product candidate is voxelotor, an oral, once-daily therapy that modulates hemoglobin's affinity for oxygen, which inhibits hemoglobin polymerization in sickle cell disease (SCD). The company is evaluating voxelotor in adult and adolescent patients with SCD in a Phase 3 clinical trial. The company is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in adolescent and pediatric patients with SCD in a Phase 2a clinical trial.
  • TickerGBT
  • ISINUS37890U1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Analyst Day Highlights Voxelotor’s Impressive Clinical Profile; KOLs Excited

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Analyst Day Highlights Voxelotor’s Impressive Clinical Profile; KOLs Excited

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Multiple SCD Presentations at SCDAA; Analyst Day on Oct 8

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold/sold after exercising options

A director at Global Blood Therapeutics Inc sold/sold after exercising options 2,765 shares at 54.357USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restrict...

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ResearchPool Subscriptions

Get the most out of your insights

Get in touch